New drug cocktail fights bile duct cancer recurrence after surgery
NCT ID NCT05254847
Summary
This study tested whether a combination of three drugs—capecitabine (a chemotherapy pill), lenvatinib (a targeted therapy), and tislelizumab (an immunotherapy)—could help prevent cancer from coming back in people who had surgery to remove bile duct cancer. The trial involved 65 patients who had successful surgery with no visible cancer left behind. Researchers measured how many patients remained cancer-free for one and two years after treatment, while also tracking side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.